论文部分内容阅读
5-氮杂胞啶具有明显的抗髓系白血病的作用。体外研究已证实小剂量5-氮杂胞啶可诱导某些未成熟细胞的分化。这种诱导分化作用与基因调节及DNA 甲基化改变有关。作者报道应用小剂量5-氮杂胞啶治疗MDS 15例,病人年龄31—76岁。治疗方案与结果:通过锁骨下静脉留置导管静脉输注本药,剂量从10mg/m~2/日到35mg/m~2/日,大部分病人接受的剂量为16.5mg/m~2/日,连续用药14日。两例病人在治疗早期由于发生血小板减少而停药,其余病人均用药满一疗程。有的病人在第一疗程结束后一个月、白细胞数恢复到治疗前水平时再开始第二疗程治疗,若第一疗程中没发生明显骨髓抑制者,第二疗程用药剂量可稍大,如25或35mg/
5-Azacytosine has a significant anti-myeloid leukemia effect. In vitro studies have demonstrated that small doses of 5-azacytidine induce the differentiation of certain immature cells. This induction of differentiation is related to gene regulation and changes in DNA methylation. The authors reported the use of low-dose 5-azacitidine in the treatment of 15 patients with MDS. The patient’s age ranged from 31 to 76 years. Treatment options and results: Intravenous indwelling catheter through the subclavian vein infusion of the drug, doses from 10mg/m~2/day to 35mg/m~2/day, most patients received a dose of 16.5mg/m~2/day , continuous medication on the 14th. Two patients were discontinued due to thrombocytopenia in the early stage of treatment, and the remaining patients were given medication for one course of treatment. Some patients will start the second course of treatment one month after the end of the first course of treatment and when the white blood cell count returns to the pre-treatment level. If no significant bone marrow suppression occurs during the first course of treatment, the dose of the second course of treatment may be slightly larger, such as 25 Or 35mg/